UCL helps put Odin Vision in the picture

Odin Vision, a UK-based bowel cancer diagnostics tool developer spun out of University College London (UCL), attracted an undisclosed sum yesterday in a round co-led by the UCL Technology Fund.
UCL Technology Fund – managed by Albion VC, the venture capital arm of Albion Capital, on behalf of UCL Business, the tech transfer office of University College London – co-led the round with publicly-owned London Co-Investment Fund and AI Seed.
Founded in 2017, Odin Vision is developing a software product that operates alongside existing endoscopy imaging systems to help clinicians detect bowel cancer, increasing the chances of successful medical treatment.
The software exploits computer vision and artificial intelligence to identify and diagnose potentially-malignant growths in the bowel – known as polyps – from the video feed of a colonoscopy.
Odin Vision will use the injection of capital to improve the accuracy and usability of its software through proof-of-concept development, before moving on to clinical trials to demonstrate the scalability of the technology.
Odin Vision is co-led by Danail Stoyanov, a professor of robot vision at UCL’s Department of Computer Science who also participates in UCL’s Centre for Medical Image Computing.
The spinout is also working on a real-time medical data analytics platform powered by cloud computing and satellite communications that would support the decision-making of doctors.
David Grimm, investment director of UCL Technology Fund, said: “Odin Vision presents an exciting opportunity in a fast-paced area of the medtech landscape.
“Its innovative software has the potential to save millions of pounds for the National Health Service, as well as offering medical treatment that clinicians can have greater conviction in.”